Author

Michael B Jameson

Waikato Hospital; University of Auckland - Cited by 3,352 - oncology

Biography

Dr. Michael B Jameson is currently working as a professor in the Waikato Clinical Campus, Faculty of Medical and Health Sciences, University of Auckland. He had published more than 125 our of his research interest. Michael B Jameson research of interests are oncology, clinical trails, Pharmacokinetics, Geriatric care, Cancer biology.
Title
Cited by
Year
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised …
AMM Eggermont, CU Blank, M Mandalà, GV Long, VG Atkinson, S Dalle, ...The lancet oncology 22 (5), 643-654, 2021202
211
2021
Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors
J Desai, S Deva, JS Lee, CC Lin, CJ Yen, Y Chao, B Keam, M Jameson, ...Journal for immunotherapy of cancer 8 (1), 2020202
89
2020
Optimising selenium for modulation of cancer treatments
SO Evans, PF Khairuddin, MB JamesonAnticancer Research 37 (12), 6497-6509, 2017201
69
2017
Phase I, open-label, dose-escalation/dose-expansion study of lifirafenib (BGB-283), an RAF family kinase inhibitor, in patients with solid tumors
J Desai, H Gan, C Barrow, M Jameson, V Atkinson, A Haydon, M Millward, ...Journal of Clinical Oncology 38 (19), 2140, 2020202
59
2020
Phase IB trial of the anti-cancer stem cell DLL4-binding agent demcizumab with pemetrexed and carboplatin as first-line treatment of metastatic non-squamous NSCLC
MJ McKeage, D Kotasek, B Markman, M Hidalgo, MJ Millward, ...Targeted Oncology 13, 89-98, 2018201
56
2018
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised …
A Bottomley, C Coens, J Mierzynska, CU Blank, M Mandalà, GV Long, ...The Lancet Oncology 22 (5), 655-664, 2021202
34
2021
The interaction of selenium with chemotherapy and radiation on normal and malignant human mononuclear blood cells
RJ Lobb, GM Jacobson, RT Cursons, MB JamesonInternational Journal of Molecular Sciences 19 (10), 3167, 2018201
27
2018
Phase 1b/2, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD-1 treatment naïve patients with recurrent or metastatic head and …
EEW Cohen, L Nabell, DJL Wong, TA Day, GA Daniels, MM Milhem, ...Journal of clinical oncology 37 (15_suppl), 6039-6039, 2019201
26
2019
Long-term follow-up of standard-dose pembrolizumab plus reduced-dose ipilimumab in patients with advanced melanoma: KEYNOTE-029 part 1B
MS Carlino, AM Menzies, V Atkinson, JS Cebon, MB Jameson, ...Clinical Cancer Research (19), 5086-5091, 2020202
26
2020
A phase Ia/Ib trial of tislelizumab, an anti-PD-1 antibody (ab), in patients (pts) with advanced solid tumors
S Deva, JS Lee, CC Lin, CJ Yen, M Millward, Y Chao, B Keam, ...Annals of Oncology 29, x24-x25, 202
18
2018
Comparative safety and pharmacokinetic evaluation of three oral selenium compounds in cancer patients
SO Evans, GM Jacobson, HJB Goodman, S Bird, MB JamesonBiological Trace Element Research 189, 395-404, 2019201
16
2019
SPAR–a randomised, placebo-controlled phase II trial of simvastatin in addition to standard chemotherapy and radiation in preoperative treatment for rectal cancer: an AGITG …
MB Jameson, K Gormly, D Espinoza, W Hague, G Asghari, GM Jeffery, ...BMC cancer 19, 1-12, 2019201
14
2019
Intralesional SD-101 in combination with pembrolizumab in anti-PD-1 treatment-naïve head and neck squamous cell carcinoma: results from a multicenter, phase II trial
EEW Cohen, L Nabell, DJ Wong, T Day, GA Daniels, M Milhem, S Deva, ...Clinical cancer research 2 (6), 1157-1166, 2022202
8
2022
Comparison of three oral selenium compounds in cancer patients: Evaluation of differential pharmacodynamic effects in normal and malignant cells
SO Evans, GM Jacobson, HJB Goodman, S Bird, MB JamesonJournal of Trace Elements in Medicine and Biology 58, 126446, 2020202
7
2020
Skin lesions suspicious for melanoma: New Zealand excision margin guidelines in practice
T Brian, MB JamesonJournal of Primary Health Care 10 (3), 210-214, 2018201
5
2018
The role of oxaliplatin in chemoradiotherapy for rectal cancer
NT Wewala, MB JamesonAsia‐Pacific Journal of Clinical Oncology 13 (6), 341-342, 2017201
5
2017
Ethnic differences in cancer rates among adults with Type 2 diabetes in New Zealand from 1994 to 2018
D Yu, Z Wang, Y Cai, K McBride, UL Osuagwu, K Pickering, J Baker, ...JAMA Network Open (2), e2147171-e2147171, 2022202
5
2022
Remote skin cancer diagnosis: Adding images to electronic referrals is more efficient than wait-listing for a nurse-led imaging clinic
L Jones, M Jameson, A OakleyCancers 13 (22), 5828, 2021202
4
2021
LONG-TERM EXPOSURE TO TISLELIZUMAB, AN INVESTIGATIONAL ANTI-PD-1 ANTIBODY, IN A FIRST-IN-HUMAN PHASE 1 STUDY
J Desai, B Markman, M Friedlander, H Gan, L Horvath, A Townsend, ...Gastric cancer 4, 6, 2019201
3
2019
Doxorubicin and cyclophosphamide-induced parotitis: a case report
A Fox-Lewis, M Tairab, G Fulton, M Kuper-Hommel, MB JamesonJournal of clinical pharmacy and therapeutics 45 (1), 211-21, 2020202
3
2020

Referred From: https://scholar.google.co.nz/citations?user=RPNE5BAAAAAJ&hl=en

Cited by
Citations 3352
h-index 30
i10-index 61
Open Access Journals